Cargando…

Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes

Autoantibodies to multiple targets are found during acute COVID-19. Whether all, or some, persist after 6 months, and their correlation with sustained anti-SARS-CoV-2 immunity, is still controversial. Herein, we measured antibodies to multiple SARS-CoV-2 antigens (Wuhan-Hu-1 nucleoprotein (NP), whol...

Descripción completa

Detalles Bibliográficos
Autores principales: Moody, Rhiane, Sonda, Sabrina, Johnston, Fay H., Smith, Kylie J., Stephens, Nicola, McPherson, Michelle, Flanagan, Katie L., Plebanski, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403331/
https://www.ncbi.nlm.nih.gov/pubmed/36032086
http://dx.doi.org/10.3389/fimmu.2022.945021
_version_ 1784773351444578304
author Moody, Rhiane
Sonda, Sabrina
Johnston, Fay H.
Smith, Kylie J.
Stephens, Nicola
McPherson, Michelle
Flanagan, Katie L.
Plebanski, Magdalena
author_facet Moody, Rhiane
Sonda, Sabrina
Johnston, Fay H.
Smith, Kylie J.
Stephens, Nicola
McPherson, Michelle
Flanagan, Katie L.
Plebanski, Magdalena
author_sort Moody, Rhiane
collection PubMed
description Autoantibodies to multiple targets are found during acute COVID-19. Whether all, or some, persist after 6 months, and their correlation with sustained anti-SARS-CoV-2 immunity, is still controversial. Herein, we measured antibodies to multiple SARS-CoV-2 antigens (Wuhan-Hu-1 nucleoprotein (NP), whole spike (S), spike subunits (S1, S2 and receptor binding domain (RBD)) and Omicron spike) and 102 human proteins with known autoimmune associations, in plasma from healthcare workers 8 months post-exposure to SARS-CoV-2 (n=31 with confirmed COVID-19 disease and n=21 uninfected controls (PCR and anti-SARS-CoV-2 negative) at baseline). IgG antibody responses to SARS-CoV-2 antigens were significantly higher in the convalescent cohort than the healthy cohort, highlighting lasting antibody responses up to 8 months post-infection. These were also shown to be cross-reactive to the Omicron variant spike protein at a similar level to lasting anti-RBD antibodies (correlation r=0.89). Individuals post COVID-19 infection recognised a common set of autoantigens, specific to this group in comparison to the healthy controls. Moreover, the long-term level of anti-Spike IgG was associated with the breadth of autoreactivity post-COVID-19. There were further moderate positive correlations between anti-SARS-CoV-2 responses and 11 specific autoantigens. The most commonly recognised autoantigens were found in the COVID-19 convalescent cohort. Although there was no overall correlation in self-reported symptom severity and anti-SARS-CoV-2 antibody levels, anti-calprotectin antibodies were associated with return to healthy normal life 8 months post infection. Calprotectin was also the most common target for autoantibodies, recognized by 22.6% of the overall convalescent cohort. Future studies may address whether, counter-intuitively, such autoantibodies may play a protective role in the pathology of long-COVID-19.
format Online
Article
Text
id pubmed-9403331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94033312022-08-26 Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes Moody, Rhiane Sonda, Sabrina Johnston, Fay H. Smith, Kylie J. Stephens, Nicola McPherson, Michelle Flanagan, Katie L. Plebanski, Magdalena Front Immunol Immunology Autoantibodies to multiple targets are found during acute COVID-19. Whether all, or some, persist after 6 months, and their correlation with sustained anti-SARS-CoV-2 immunity, is still controversial. Herein, we measured antibodies to multiple SARS-CoV-2 antigens (Wuhan-Hu-1 nucleoprotein (NP), whole spike (S), spike subunits (S1, S2 and receptor binding domain (RBD)) and Omicron spike) and 102 human proteins with known autoimmune associations, in plasma from healthcare workers 8 months post-exposure to SARS-CoV-2 (n=31 with confirmed COVID-19 disease and n=21 uninfected controls (PCR and anti-SARS-CoV-2 negative) at baseline). IgG antibody responses to SARS-CoV-2 antigens were significantly higher in the convalescent cohort than the healthy cohort, highlighting lasting antibody responses up to 8 months post-infection. These were also shown to be cross-reactive to the Omicron variant spike protein at a similar level to lasting anti-RBD antibodies (correlation r=0.89). Individuals post COVID-19 infection recognised a common set of autoantigens, specific to this group in comparison to the healthy controls. Moreover, the long-term level of anti-Spike IgG was associated with the breadth of autoreactivity post-COVID-19. There were further moderate positive correlations between anti-SARS-CoV-2 responses and 11 specific autoantigens. The most commonly recognised autoantigens were found in the COVID-19 convalescent cohort. Although there was no overall correlation in self-reported symptom severity and anti-SARS-CoV-2 antibody levels, anti-calprotectin antibodies were associated with return to healthy normal life 8 months post infection. Calprotectin was also the most common target for autoantibodies, recognized by 22.6% of the overall convalescent cohort. Future studies may address whether, counter-intuitively, such autoantibodies may play a protective role in the pathology of long-COVID-19. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403331/ /pubmed/36032086 http://dx.doi.org/10.3389/fimmu.2022.945021 Text en Copyright © 2022 Moody, Sonda, Johnston, Smith, Stephens, McPherson, Flanagan and Plebanski https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Moody, Rhiane
Sonda, Sabrina
Johnston, Fay H.
Smith, Kylie J.
Stephens, Nicola
McPherson, Michelle
Flanagan, Katie L.
Plebanski, Magdalena
Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
title Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
title_full Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
title_fullStr Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
title_full_unstemmed Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
title_short Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
title_sort antibodies against spike protein correlate with broad autoantigen recognition 8 months post sars-cov-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403331/
https://www.ncbi.nlm.nih.gov/pubmed/36032086
http://dx.doi.org/10.3389/fimmu.2022.945021
work_keys_str_mv AT moodyrhiane antibodiesagainstspikeproteincorrelatewithbroadautoantigenrecognition8monthspostsarscov2exposureandanticalprotectinautoantibodiesassociatedwithbetterclinicaloutcomes
AT sondasabrina antibodiesagainstspikeproteincorrelatewithbroadautoantigenrecognition8monthspostsarscov2exposureandanticalprotectinautoantibodiesassociatedwithbetterclinicaloutcomes
AT johnstonfayh antibodiesagainstspikeproteincorrelatewithbroadautoantigenrecognition8monthspostsarscov2exposureandanticalprotectinautoantibodiesassociatedwithbetterclinicaloutcomes
AT smithkyliej antibodiesagainstspikeproteincorrelatewithbroadautoantigenrecognition8monthspostsarscov2exposureandanticalprotectinautoantibodiesassociatedwithbetterclinicaloutcomes
AT stephensnicola antibodiesagainstspikeproteincorrelatewithbroadautoantigenrecognition8monthspostsarscov2exposureandanticalprotectinautoantibodiesassociatedwithbetterclinicaloutcomes
AT mcphersonmichelle antibodiesagainstspikeproteincorrelatewithbroadautoantigenrecognition8monthspostsarscov2exposureandanticalprotectinautoantibodiesassociatedwithbetterclinicaloutcomes
AT flanagankatiel antibodiesagainstspikeproteincorrelatewithbroadautoantigenrecognition8monthspostsarscov2exposureandanticalprotectinautoantibodiesassociatedwithbetterclinicaloutcomes
AT plebanskimagdalena antibodiesagainstspikeproteincorrelatewithbroadautoantigenrecognition8monthspostsarscov2exposureandanticalprotectinautoantibodiesassociatedwithbetterclinicaloutcomes